Navigation Links
Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
Date:9/3/2007

Report of Positive Results with Innovative Pro-Healing Stent is Featured at

ESC Congress 2007

VIENNA, Austria, Sept. 3 /PRNewswire/ -- OrbusNeich today announced that post-marketing data from patient subsets of a global registry support the use of the company's Genous(TM) Bio-engineered R stent(TM) as an alternative to drug-eluting stents.

Presented today by Robbert de Winter, M.D., Ph.D., at the European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from OrbusNeich's e-HEALING registry show:

* For 296 diabetic patients at six months, the target lesion

revascularization (TLR) rate was 2%, which is much lower than was

anticipated

* A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]

six months

* For 923 patients with statin use, the major adverse cardiac events

(MACE) rate at six months was 5.7%, while 116 patients without statin

use experienced a MACE rate of 6.9% over the same period

"This real-world data strengthen our belief that Genous is a very promising alternative to drug-eluting stents," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "Genous appears to have the same efficacy as drug-eluting stents but a better safety profile with only minimal dual-antiplatelet therapy requirements. This is an important finding in that physicians are becoming reluctant to burden their patients with the cost and compliance issues associated with drug-eluting stents and their extensive dual-antiplatelet therapy requirements."

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry of patients treated with the Genous Bio- engineered R stent in accordance with the instructions for use. The protocol recommends that patients receive two weeks of statin treatment prior to the procedure and one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary outcome of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patient’s perception of health status helps in better recover
7. HIV infected patients can travel safely abroad
8. New vaccine helps allergy and asthma patients
9. Doctors operate upon patients in candlelight- latest from the quake scene
10. New vaccine helps allergy and asthma patients
11. Are cancer patients being taken for a ride?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
Breaking Medicine Technology: